Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Gilead ...

After hours: February 4 at 6:59:40 PM EST Loading Chart for GILD ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pre-Market: 8:05:06 a.m. EST ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to $1.7B to jointly develop and commercialize LEO’s anti-inflammatory drugs ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield Investor model based on the published ...